Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM512 in moderate-to-severe atopic dermatitis
NCT06947980Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CM512 in atopic dermatitis (AD) (5 arms), sponsored by Keymed Biosciences. Primary endpoint: Eczema Area and Severity Index at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
CM512
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06947980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947980.